Streetbeat News

Partnerships

LDOS

Leidos (NYSE:LDOS) has been awarded a $276 million contract by the Department of Defense to conduct R&D on critical minerals and materials for munitions, enhancing supply chain resiliency.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:01 pm

BNTX

GMAB

MRNA

PFE

BioNTech reported a significant Q2 loss due to lower demand for its COVID-19 vaccine and increased R&D spending on new cancer products. The company missed earnings and sales expectations, with a net loss of 807.8 million euros. BioNTech's partner, Pfizer, raised its 2024 guidance, while Moderna lowered its sales guidance. Genmab will take over the development of acasunlimab from BioNTech.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 11:59 am

DCGO

DocGo has announced the launch of a mobile X-ray program in partnership with MinXray, aiming to enhance its healthcare services.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:39 am

ALZN

Alzamend Neuro shares are trading higher following the announcement of a partnership with Massachusetts General Hospital for a Phase II trial of AL001.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:37 am

REKR

Rekor Systems, Inc. (NASDAQ:REKR) has launched its Strategic Corridor Monitoring project, funded by a $1.5M federal and state grant. The project will deploy AI-powered sensors to provide real-time traffic insights for the Maryland Department of Transportation State Highway Administration (MDOT).

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:37 am

LNG

Cheniere Energy (NYSE:LNG) has signed a 20-year LNG sale and purchase agreement with Galp Trading S.A., a subsidiary of Galp Energia. Galp will purchase 0.5 million tonnes of LNG annually from Cheniere starting in the early 2030s, contingent on the completion of the Sabine Pass Liquefaction Expansion Project.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:33 am

ALZN

Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II trial of AL001, targeting Alzheimer's disease patients.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

ATNM

The FDA has determined that Actinium Pharmaceuticals' Phase 3 Sierra Trial is not adequate to support a BLA filing for Iomab-B for relapsed or refractory acute myeloid leukemia, despite achieving its primary endpoint. Actinium will need to conduct an additional head-to-head randomized clinical trial to demonstrate overall survival benefit. The company plans to request a meeting with the FDA to discuss the specifics and will seek a strategic partner for Iomab-B in the U.S. Actinium will also focus on developing Actimab-A, Iomab-ACT, and preclinical programs.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:12 am

UCAR

U Power Limited (NASDAQ:UCAR) has signed a Memorandum of Understanding with Velo Labs to establish a blockchain-based EV battery investment ecosystem in Thailand. This collaboration aims to enhance battery tracking, user experience, and operational efficiency, and attract external funding for large-scale development.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:09 am

GHM

Graham Corporation (NYSE:GHM) has secured over $65 million in defense and space contracts, including support for the MK48 Mod 7 Heavyweight Torpedo program, the MK19 air turbine pump for Columbia-class submarines, and a cryogenic recirculation pump for space launch vehicles. Revenue from these contracts will be recognized over the next three to eight years.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 10:57 am